Pharvaris (NASDAQ:PHVS) Director Viviane Monges Sells 9,667 Shares of Stock

Pharvaris N.V. (NASDAQ:PHVS) Director Viviane Monges sold 9,667 shares of Pharvaris stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $30.29, for a total transaction of $292,813.43. Following the transaction, the director directly owned 5,500 shares in the company, valued at $166,595. This represents a 63.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Pharvaris Price Performance

PHVS opened at $29.88 on Wednesday. The company has a market capitalization of $1.95 billion, a price-to-earnings ratio of -9.40 and a beta of -2.34. The firm’s fifty day moving average price is $28.61 and its two-hundred day moving average price is $26.96. Pharvaris N.V. has a 1 year low of $15.46 and a 1 year high of $33.33.

Pharvaris (NASDAQ:PHVS) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.12. As a group, equities analysts anticipate that Pharvaris N.V. will post -3.25 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Wall Street Zen raised shares of Pharvaris from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Pharvaris in a report on Tuesday, April 21st. Wolfe Research assumed coverage on shares of Pharvaris in a report on Thursday, April 9th. They issued an “outperform” rating and a $42.00 price target on the stock. Citizens Jmp cut their price target on shares of Pharvaris from $75.00 to $74.00 and set a “market outperform” rating on the stock in a report on Wednesday, May 13th. Finally, Wedbush boosted their price target on shares of Pharvaris from $41.00 to $42.00 and gave the stock an “outperform” rating in a report on Tuesday, April 7th. Ten analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Pharvaris currently has a consensus rating of “Moderate Buy” and a consensus target price of $49.18.

Hedge Funds Weigh In On Pharvaris

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Stempoint Capital LP lifted its holdings in Pharvaris by 48.4% during the first quarter. Stempoint Capital LP now owns 86,637 shares of the company’s stock valued at $2,447,000 after purchasing an additional 28,248 shares during the last quarter. ADAR1 Capital Management LLC lifted its holdings in Pharvaris by 23.4% during the first quarter. ADAR1 Capital Management LLC now owns 105,528 shares of the company’s stock valued at $2,981,000 after purchasing an additional 20,000 shares during the last quarter. Amundi lifted its holdings in Pharvaris by 12.0% during the first quarter. Amundi now owns 30,952 shares of the company’s stock valued at $874,000 after purchasing an additional 3,312 shares during the last quarter. Rock Springs Capital Management LP lifted its holdings in Pharvaris by 3.6% during the first quarter. Rock Springs Capital Management LP now owns 645,533 shares of the company’s stock valued at $18,236,000 after purchasing an additional 22,131 shares during the last quarter. Finally, SummitTX Capital L.P. lifted its holdings in Pharvaris by 27.7% during the first quarter. SummitTX Capital L.P. now owns 29,184 shares of the company’s stock valued at $824,000 after purchasing an additional 6,325 shares during the last quarter.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.